Recombinant-HB: Perspectives past, present and future

Expert Review of Vaccines

Volumn 3, Issue 2, 2004, Pages 119-129

  Venters, Charmaine L ^a   Graham Jr , William J ^a   Cassidy, William M ^a   Denham, Sean ^b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Department of Internal Medicine ^*

Author keywords

Hepatitis B; Hepatocellular carcinoma; Heptavax ; Immunogenicity; Immunologic memory; Recombivax HB

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; EMTRICITABINE; ENGERIX; ENTECAVIR; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPAGEN; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; LAMIVUDINE; PEDIARIX; RECOMBINANT HEPATITIS B VACCINE; TELBIVUDINE; THIOMERSAL; UNCLASSIFIED DRUG; VACCINE; RECOMBINANT VACCINE;

ALLERGIC REACTION; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFECTIOUS HEPATITIS; LIVER CELL CARCINOMA; MASS IMMUNIZATION; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; CHILD; IMMUNIZATION; IMMUNOLOGY; INFANT; METHODOLOGY; NEWBORN; PRESCHOOL CHILD; VACCINATION;

CHILD; CHILD, PRESCHOOL; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; VACCINATION; VACCINES, SYNTHETIC;

EID: 1842736011     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.2.119     Document Type: Review

References (76)

1. The Centers for Disease Control (CDC). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 40(RR-13), 1-25 (1991).
2. Chang MH, Chen JC, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N. Eng. J. Med 336, 1855-1859 (1997).
3. Krugman S, Giles JP, Hammond J. Viral hepatitis, type B (MS-2 strain): studies on active immunization. JAMA 217, 41-45 (1971).
4. McQuillan GM, Colemen PJ, Kruszon-Moran D et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am. J. Public Health 89, 11-13 (1999).
5. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin. Liver Dis. 11, 84-92 (1991).
6. World Health Organization (WHO). Progress in the control of viral hepatitis: Memorandum from a WHO meeting. Bulletin WHO 66, 453-455 (1988).
7. Melnick JL. Historical aspects of hepatitis B vaccine. In: Hepatitis B Vaccine Inserm. Symp. No. 18. Maupas P, Guesry P (Eds), Elsevier/North-Holland Biomedical Press, Amsterdam, Netherlands 23-31 (1991).
8. Seeff LB, Wright EC, Zimmerman HJ et al. Type B hepatitis after needle stick exposure: prevention with hepatitis B immunoglobulin. Final report of the Veterans Administration Cooperative Study. Ann. Int. Med. 88, 285-293 (1978).
9. The Centers for Disease Control (CDC). Inactivated hepatitis B virus vaccine. MMWR 31, 317-328 (1982).
10. The Centers for Disease Control (CDC). Recommendations of the Immunisation Practices Advisory Committee: Recommendations for protection against viral hepatitis. MMWR 34, 329-335 (1985).
11. International Group. Immunization against hepatitis B. Lancet 1, 875-876 (1988).
12. WHO. Informal consultation in quadrivalent diptheria-tetanus-pertussis-hepatitis B vaccine: final report. Geneva: WHO 1-12 (1992).
13. Francis DP, Feorino PM, McDougal S et al. The safety of the hepatitis B vaccine: Inactivation of the AIDS virus during routine manufacture. JAMA 25, 869-871 (1986).
14. McAleer WJ, Buynak EB, Maigetter RZ et al. Human hepatitis B vaccine from recombinant yeast. Nature 307, 178-180 (1984).
15. Emini EA, Ellis RW, Miller WJ et al. Production and immunological analysis of recombinant hepatitis B vaccine. J. Infect. 13(Suppl. A), 3-9 (1986).
16. Davidson M, Krugman S. Recombinant yeast hepatitis B vaccine compared with plasma-derived vaccine: immunogenicity and effect of a booster dose. J. Infect. 13(Suppl. A), 31-38 (1986).
17. Jilg W, Lorbeer B, Schmidt M et al. Clinical evaluation of a recombinant hepatitis B vaccine. Lancet 2, 1174-11 (1984).
18. Davidson M, Krugman S. Immunogenicity of recombinant yeast hepatitis B vaccine. Lancet 1, 108-109 (1985).
19. Papaevangelou G, Dandolos E, Roumeliotou-Karayannis A et al. Immunogenicity of recombinant hepatitis B vaccine. Lancet 1, 455-456 (1985).
20. Brow SE, Stanley C, Howard CR et al. Antibody responses to recombinant and plasma-derived hepatitis B vaccine. Br. Med. J. 292, 159-161 (1986).
21. Hollinger FB, Troisi CL, Pepe PE. Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast. J. Infect. Dis. 153, 156-159 (1986).
22. CDC. Recommendations of the Immunization Practices Advisory Committee update on hepatitis B prevention. MMWR 36, 353-366 (1987).
23. WHO. Progress in the control of viral hepatitis: Memorandum from a WHO meeting. Bull. WHO 66, 443-455 (1988).
24. Kane MA, Bezabeh S. Hepatitis B vaccination: challenges and solutions. In: Viral Hepatitis and Liver Disease. Rizzetto M, Murcell RH, Gerin JL, Verme G (Eds), Edizioni Minerva Medica, Turin, Italy 938-939 (1997).
25. CDC. Recommendations of the immunization practices advisory committee: recommendations for protection against viral hepatitis. MMWR 34, 329-335 (1985).
26. Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J. Inf Dis. 160, 766-769 (1989).
27. Wong V, Woodruff C, Shapiro R. Compliance of hepatitis B vaccination in patients presenting to a teenage clinic. Ped. Inf. Dis. J. 13, 936 (1994).
28. Cassidy W, Mahoney F. A hepatitis B vaccination program targeting adolescents. J. Adol. Health 17, 244-247 (1995).
29. The Centers for Disease Control (CDC). Notice to readers: alternate two-dose hepatitis B vaccination schedule for adolescents aged 11-15 years. MMWR 49, 261 (2000).
30. Cassidy W, Watson B, Ioli V et al. A randomized trail of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics 107, 626-631 (2001).
31. Poland G. Adolescent hepatitis B immunization: making it simpler. Pediatrics 107, 771-772 (2001).
32. The Centers for Disease Control (CDC). Effectiveness of a seventh-grade school entry vaccination requirement-statewide and Orange County, Florida, 1997-1998. MMWR 47, 711-715 (1998).
33. The Centers for Disease Control (CDC). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee. MMWR 40(RR-13), 1-25 (1991).
34. Stevens C, Toy P, Tong M et al. Perinatal hepatitis B virus transmission in the United States. JAMA 253, 1740-1744 (1985).
35. Kumar M, Dawson N, McCollough A et al. Should all pregnant women be screened for hepatitis B. Ann. Int. Med. 107, 272-277 (1987).
36. CDC. MMWR 33, 285-290 (1984) and MMWR 34, 313-324; 329-335 (1985).
37. CDC. MMWR 33, 285-290 (1984) and MMWR 34, 313-324; 329-335 (1985).
38. Jonas M, Schiff E, O'Sullivan M et al. Failure of Centers for Disease Control criteria to identify hepatitis B infection in a large municipal obstetrical population. Ann. Int. Med. 107, 335-337 (1987).
39. McMahon B, Heyward W, Ritter D et al. A comprehensive program to reduce the incidence of hepatitis B virus infection and its sequela in Alaskan Natives. Lancet 1134-1135 (1987).
40. Durand AM, Sabino H JR, Mahoney F. Success of mass vaccination of infants against hepatitis B. JAMA 276, 1802-1803 (1996).
41. Stevens C, Taylor P, Tong M et al. Yeast recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 257, 2612-2616 (1987).
42. Lolekha S, Warachit B, Hirunyachote A et al. Protective efficacy of hepatitis B without HBIG in infants of HBsAg-positive carrier mothers in Thailand. Vaccine 20, 3739-3743 (2002).
43. Franks A, Berg C, Kane M et al. Hepatitis B virus infection among children born in the United States to southeast Asian refugees. N. Eng. J. Med. 321, 1301-1304 (1989).
44. Keyserling H, West D, Hesley T et al. Antibody responses of healthy infants to a recombinant hepatitis B vaccine administered at two, four, and twelve to fifteen months of age. J. Pedaitr. 125, 67-69 (1994).
45. West D, Watson B, Lichtman J, Hesley T, Hedberg K. Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy. J. Ped. Inf. Dis. 13, 645-646 (1994).
46. CDC. Notice to readers: FDA approval of changes in pediatric formulation for Recombivax-HB®. MMWR 48, 34-35 (1999).
47. Advisory Committee on Immunization Practices. Redbook. Pickering L (Ed.), American Academy of Pediatrics, IL, USA 24-25 (2003).
48. American Academy of Pediatrics Committee on Infectious Diseases. Universal hepatitis B immunization. Pediatrics 37, 585-601 (1992).
49. Kim S, Chung E, Hodinka R et al. Immunogenicity of hepatitis B vaccine in preterm infants. Pediatrics 99, 534-536 (1997).
50. Chirico B, Belloni C, Gasparoni A et al. Hepatitis B immunization in infants of hepatitis B surface antigen-negative mothers. Pediatrics 92, 717-719 (1993).
51. Del Canho R, Grosheide P, Gerards L et al. Hepatits B vaccination and preterm infants. J. Ped. Inf. Dis. 12, 407-408 (1993).
52. Chawareewong S, Jirapongsa A, Lokaphadhana K. Immune response to hepatitis B vaccine in premature neonates. Southeast Asian J. Trop. Med. Public Health 22, 39-40 (1991).
53. Lau K, Tam A, et al. Response of preterm infants to hepatitis B vaccine. J. Pedaitr. 121, 962-965 (1992).
54. Losonsky J, Wasseramn S, West D et al. Hepatitis B vaccination in preterm infants; a reassessment of current recommendations for delayed immunization. Pediatrics 103, 2 (1999).
55. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 272, 54-60 (1996).
56. Wilson JN, Nokes DJ. Do we need three doses of hepatitis B vaccine? Vaccine 17, 2667-2673 (1999).
57. Wistrom J, Ahlm C, Lundberg S et al. Booster vaccination with recombinant hepatitis B vaccine 4 years after priming with one single dose. Vaccine 17, 2162-2165 (1999).
58. Jilg W, Schmidt M, Deinhardt F. Immune response to hepatitis B revaccination. J. Med. Virol. 24, 377-384 (1985).
59. Biggar RJ, Goedert JJ, Hoofnagle J. Acclerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV. N. Engl. J. Med. 316, 630-631 (1987).
60. The Centers for Disease Control (CDC). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee. MMWR 40(RR-13), 1-25 (1991).
61. The Centers for Disease Control (CDC). MMWR Recommendations and Reports 50 (RR-05), 1-43 (2001).
62. Seto D, West D, Ioli V. Persistence of antibody and immunologic memory in children immunized with hepatitis B vaccine at birth. J. Ped. Inf. Dis. 21, 793-794 (2002).
63. Marsano L, West D, Chan I et al. A two-dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults. Vaccine 16(6), 624-629 (1998).
64. Ostrow DJ, Goldsmith J et al. Nonresponse to hepatitis B vaccine in homosexual men. Sex. Transm. Dis. 14, 92-97 (1987).
65. Janssen H, Hess G, Rossol S et al. Antiviral effect of prolonged intermittent lymphoblastoid interferon treatment in chronic hepatitis B. Gut 33(8), 1094-1098 (1992).
66. Andre FE. Summary of efficacy and safety data on a yeast-derived hepatitis B vaccine. Am. J. Med. 87(Suppl. 3A), 14S-20S (1989).
67. WHO. Expanded Programme on Immunisation (EPI). Lack of evidence that hepatitis B vaccine causes multiple sclerosis. Wkly Epidemiol. Rec. 72, 149-152 (1997).
68. Ascherio A, Zhang SM, Hernan MA et al. Hepatitis B vaccination and the risk of multiple sclerosis. N. Engl. J. Med. 344, 327-332 (2001).
69. Confraveux C, Suissa S, Saddier P et al. Vaccination and the risk of relapse in multiple sclerosis. N. Engl. J. Med. 344, 327-332 (2001).
70. Sadonvick AD, Scheifele DW. School-based hepatitis B vaccination program and adolescent multiple sclerosis. Lancet 355, 549-550 (2000).
71. The Centers for Disease Control (CDC). MMWR 49(27), 622-631 (2000).
72. West D, Hesley T, Jonas L et al. Safety and immunogenicity of a bivalent Haemophilus influenzae type b/Hepatitis B vaccine in healthy infants. J. Ped. Inf. Dis. 16, 593-599 (1997).
73. Chang MH, Chen JC, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of heaptocellular carcinoma in children. N. Eng. J. Med. 336, 1855-1859 (1997).
74. Website of the Hepatitis B Foundation. www.hepb.org Accessed March, 2004
75. World Health Organization documents. www.who.int/vaccines-documents/DoxNews/pdf-updt/updat31e.pdf Accessed March, 2004
76. Website of the National Center for Infectious Diseases, Travellers' Health. www.cdc.gov/travel/diseases/hbv.htm Accessed March, 2004